Antitumor efficacy of CTX in combination with conventional chemotherapy has been proven in various EGFR-expressing malignancies like colorectal cancer, head and neck cancers and recurrent NPC [25–27]. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.